文献速递淋巴瘤

CD19嵌合抗原受体T细胞疗法治疗难治性侵袭性B细胞淋巴瘤

CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2018-12-13

本综述讨论三种抗CD19嵌合抗原受体T细胞产品治疗化疗不敏感侵袭性B细胞非霍奇金淋巴瘤时,疗效与毒性数据之外的混杂因素,包括生产可靠性和总体成本,并分析领域发展方向及提高疗效、降低毒性的策略。作者认为因随机三臂临床试验不太可能开展,产品选择或需依据同时使用过三种产品的治疗中心的结果,但届时结果可能已过时。

要点

  • 两种抗CD19 CAR T细胞产品已获美国食品药品监督管理局批准用于化疗不敏感侵袭性B细胞非霍奇金淋巴瘤,第三种产品预计数月内获批。
  • 选择产品不能仅比较报告的疗效与毒性结果,还需考虑生产可靠性和总体成本等混杂因素。
  • 随机三臂临床试验不太可能开展,产品选择或需依据有全部三种产品使用经验的治疗中心的结果,但届时结果可能已过时。

核心结论

  • 因随机三臂临床试验不太可能开展,产品选择或需依据有全部三种产品使用经验的治疗中心的结果,但届时结果可能已过时,因为领域快速演进,下一个产品可能已经出现。

研究设计与样本

  • 本综述概述三种抗CD19 CAR T细胞产品及其关键临床试验中的潜在混杂因素,并强调在比较产品时需考虑生产可靠性和总体成本。
  • 本综述还回顾领域发展方向及正在研究的提高疗效和降低毒性的策略。

主要发现

  • 两种抗CD19 CAR T细胞产品已获美国食品药品监督管理局批准用于治疗化疗不敏感侵袭性B细胞非霍奇金淋巴瘤患者,第三种产品预计数月内获批。
  • 回答「是否有首选或最佳产品」比简单平衡报告的疗效和毒性结果更复杂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 随机三臂临床试验不太可能开展。
  • 依据有全部三种产品使用经验的治疗中心结果选择产品时,结果可能已过时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the treatment of chemotherapy-insensitive aggressive B-cell non-Hodgkin lymphoma (B-NHL). There are now two US Food and Drug Administration (FDA)-approved products available for treating these patients, and a third product is expected to be approved in the coming months. The question remains: Is there a preferred or best product for my patient? However, answering that question is more complicated than simply balancing the reported efficacy and toxicity results. DESIGN: This review outlines potential confounding factors involving the three products and their pivotal clinical trials and highlights additional considerations of manufacturing reliability and overall cost that must be considered when weighing one product against another. It will also review the directions in which the field is moving and strategies being examined to improve efficacy as well as toxicity. CONCLUSION: Because a randomized three-arm clinical trial is unlikely, a product may have to be chosen on the basis of results from treatment centers that have experience with all three products. But by the time those results are available, they are likely to be outdated because, given the rapid evolution of the field, the next product will probably have been identified.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jacobson CA. CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. J Clin Oncol. 2018. PMID: 30557517. doi:10.1200/JCO.18.01457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。